Charles River Laboratories refinanced its existing $1 billion revolving credit facility due 2021 with a new $1.55 billion revolving credit facility due 2023 and its existing $650 million term loan facility due 2021 with a new $750 million term loan facility due 2023.
According to a related 8-K filing, JPMorgan served as administrative agent on the transaction.
Charles River intends to use the net proceeds of the credit facilities to fund the cash consideration and other amounts payable, including the repayment of certain outstanding indebtedness, for its previously announced acquisition of MPI Research, along with related fees and expenses.
